8 research outputs found
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system
Several surgical treatments are available for managing lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Water vapor thermal therapy (WVTT) is a new minimally invasive therapy. This study estimates the budget impact of introducing WVTT for LUTS/BPH into the Spanish health care system. A model simulated the evolution of men over 45 years of age with moderate-severe LUTS/BPH after surgical treatment, over a 4-year time horizon, from the Spanish public health care service´s perspective. The technologies in scope included those most used in Spain: WVTT, transurethral resection (TURP), photoselective laser vapourization (PVP) and holmium laser enucleation (HoLEP). Transition probabilities, adverse events and costs were identified from the scientific literature and validated by a panel of experts. Sensitivity analyses were performed by varying the most uncertain parameters. Per intervention, WVTT resulted in savings of €3,317, €1,933 and €2,661 compared to TURP, PVP and HoLEP. Over a 4-year time horizon, when performed in 10% of the cohort of 109,603 Spanish males with LUTS/BPH, WVTT saved €28,770,125 against the scenario without WVTT availability. WVTT could reduce the cost of managing LUTS/BPH, increase the quality of health care and reduce the length of procedure and hospital stay.</p
Comparison of baseline characteristics; mono-infected <i>vs</i>. co-infected patients.
<p>Comparison of baseline characteristics; mono-infected <i>vs</i>. co-infected patients.</p
AUROC curve analysis for R<sub>D1L</sub>, including the overall cohort (0.79; p<0.001), the estimation cohort (0.77; p<0.001) and the validation cohort (0.71; p<0.001)
<p>AUROC curve analysis for R<sub>D1L</sub>, including the overall cohort (0.79; p<0.001), the estimation cohort (0.77; p<0.001) and the validation cohort (0.71; p<0.001)</p
Variables associated with RVR in multivariate analysis of the estimation cohort.
<p>Variables associated with RVR in multivariate analysis of the estimation cohort.</p
The decision tree based on sensitivity of the proposed prognostic tool to predict RVR and D1L.
<p>The decision tree based on sensitivity of the proposed prognostic tool to predict RVR and D1L.</p
Rapid virological response in patients segregated with respect to mono-infection or co-infection
<p>Rapid virological response in patients segregated with respect to mono-infection or co-infection</p
AUROC curve analysis for R<sub>RVR</sub>, including the overall cohort (0.82; p<0.001), the estimation cohort (0.83; p<0.001) and the validation cohort (0.82; p<0.001)
<p>AUROC curve analysis for R<sub>RVR</sub>, including the overall cohort (0.82; p<0.001), the estimation cohort (0.83; p<0.001) and the validation cohort (0.82; p<0.001)</p